FINWIRES · TerminalLIVE
FINWIRES

研究报告提醒:我们维持对捷普公司的“持有”评级。

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将目标股价从272美元上调至320美元,约为我们2027财年每股收益预期值的22倍,这反映出我们对JBL业务组合向高利润率的智能基础设施领域转型充满信心。我们将2027财年每股收益预期从14.00美元上调至14.70美元,并维持2026财年每股收益预期在12.25美元不变。我们信心增强的原因在于多个因素的共同作用。随着客户恢复对关键基础设施项目的资本支出,受监管行业的持续复苏势头正在增强。与此同时,互联生活和数字商务等业务板块正在经历意义深远的转型,向高利润率的自动化和机器人解决方案转型,逐步摆脱低利润率的传统制造业。这使得JBL在2027财年有望加速盈利增长,而2026财年则已初见成效。我们相信JBL正成功转型,朝着更盈利的商业模式迈进,而我们认为,这种积极的发展势头已在很大程度上反映在了当前的估值中。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF